Abstract
Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Current Pharmaceutical Design
Title:CNS Transporters and Drug Delivery in Epilepsy
Volume: 20 Issue: 10
Author(s): Heidrun Potschka and Hiram Luna-Munguia
Affiliation:
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Abstract: Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Export Options
About this article
Cite this article as:
Potschka Heidrun and Luna-Munguia Hiram, CNS Transporters and Drug Delivery in Epilepsy, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990461
DOI https://dx.doi.org/10.2174/13816128113199990461 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Protein Tyrosine Phosphatases in Plants
Current Genomics Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines
CNS & Neurological Disorders - Drug Targets Early Age of Migraine Onset is Independently Related to Cognitive Decline and Symptoms of Depression Affect Quality of Life
Current Neurovascular Research Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Novel Pharmacological Targets From Indian Cone Snails
Mini-Reviews in Medicinal Chemistry Design, Synthesis and in silico Studies of New 5-substituted-2-(2-(5-aryl- 1H-1, 2, 4-triazole-3-ylthio) acetyl) Hydrazine Carbothioamide/ Carboxamides for Anticonvulsant Activity
Letters in Drug Design & Discovery Preface
Current Pharmaceutical Design Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design The Effect of Lamotrigine on Valproic Acid Concentrations
Current Drug Safety The Role of Innate Immune System Receptors in Epilepsy Research
CNS & Neurological Disorders - Drug Targets Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Drug Repositioning: A Unique Approach to Refurbish Drug Discovery
Current Drug Discovery Technologies Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets Chemistry, Biological Properties and SAR Analysis of Quinoxalinones
Mini-Reviews in Medicinal Chemistry Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches
CNS & Neurological Disorders - Drug Targets